Neurogenic bladder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:32 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Neurogenic bladder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of Vibegron for Children Aged 2 to 17 with Neurogenic Bladder Overactivity Using Clean Intermittent Catheterization https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-vibegron-for-children-aged-2-to-17-with-neurogenic-bladder-overactivity-using-clean-intermittent-catheterization/ Wed, 29 Apr 2026 15:01:37 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-vibegron-for-children-aged-2-to-17-with-neurogenic-bladder-overactivity-using-clean-intermittent-catheterization/ This clinical trial is focused on studying a condition called Neurogenic Detrusor Overactivity (NDO), which affects the bladder’s ability to store urine properly. The study involves children and teenagers aged 2 to under 18 years who use a method called Clean Intermittent Catheterization (CIC) to help empty their bladders. The treatment being tested is a medication called Vibegron, which is taken orally in the form of granules or film-coated tablets. The purpose of the study is to evaluate the safety and effectiveness of Vibegron in managing NDO symptoms in young patients.

Participants in the study will receive Vibegron over a period of up to 52 weeks. During this time, they will have regular check-ups to monitor their health and the effects of the medication. The study will also involve assessments to understand how the body processes the medication, known as pharmacokinetics. This includes measuring how much of the drug is in the blood at different times and how long it stays in the body.

The study aims to see if Vibegron can help improve bladder function and reduce symptoms associated with NDO. Participants will be observed for changes in bladder activity and any side effects they might experience. The study will also look at how the treatment affects the participants’ quality of life over time. This research is important for finding better ways to manage NDO in children and teenagers, potentially leading to improved treatments in the future.

]]> Study on E. coli Polysaccharide for Reducing Antibiotic Use in Patients with Neurogenic Bladder and Recurrent Urinary Tract Infections https://clinicaltrials.eu/trial/study-on-e-coli-polysaccharide-for-reducing-antibiotic-use-in-patients-with-neurogenic-bladder-and-recurrent-urinary-tract-infections/ Wed, 29 Apr 2026 15:00:30 +0000 https://clinicaltrials.eu/trial/study-on-e-coli-polysaccharide-for-reducing-antibiotic-use-in-patients-with-neurogenic-bladder-and-recurrent-urinary-tract-infections/ This clinical trial is focused on studying the effects of a treatment for people with a condition known as neurogenic bladder, which often leads to recurrent urinary tract infections (UTIs). Neurogenic bladder is a condition where the nerves that control the bladder are damaged, often due to a spinal cord injury, leading to difficulties in bladder control. The treatment being tested is called OM-89, which is a type of bacterial vaccine made from parts of the E. coli bacteria. This study will compare the effects of OM-89 with a placebo to see if it can reduce the need for antibiotics in treating UTIs.

The purpose of the study is to evaluate whether OM-89 can help reduce the number of antibiotic treatments needed for UTIs in patients with a stabilized neurogenic bladder. Participants in the study will receive either OM-89 or a placebo and will be monitored over a period of time to see how often they need antibiotics for UTIs. The study will also look at the number of UTIs, hospitalizations due to UTIs, and the overall quality of life of the participants.

Throughout the study, participants will be asked to take the treatment orally in the form of capsules. The study will last for several months, and participants will have regular check-ups to monitor their health and any changes in their condition. The goal is to find out if OM-89 can effectively reduce the frequency of UTIs and the need for antibiotics, which can help improve the quality of life for people with neurogenic bladder.

]]> Study on the Safety and Effectiveness of Mirabegron for Children Aged 6 Months to Under 3 Years with Neurogenic Detrusor Overactivity https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-mirabegron-for-children-aged-6-months-to-under-3-years-with-neurogenic-detrusor-overactivity/ Wed, 29 Apr 2026 14:25:49 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-mirabegron-for-children-aged-6-months-to-under-3-years-with-neurogenic-detrusor-overactivity/ This clinical trial is focused on studying a condition known as Neurogenic Detrusor Overactivity (NDO), which is a type of overactive bladder caused by nerve problems. The study is specifically for children aged 6 months to less than 3 years who have this condition. The treatment being tested is a medication called Mirabegron, which is given as a prolonged-release oral suspension. This means the medicine is in liquid form and is designed to release slowly in the body over time.

The purpose of the study is to evaluate how effective and safe Mirabegron is for treating symptoms of an overactive bladder in young children with a neurological cause. The study will also look at how long the medication stays in the body. Participants will receive the medication in gradually increasing doses, followed by a period where they receive a fixed dose. The study will last for up to 52 weeks, during which the children will be monitored for any changes in their condition and any side effects they might experience.

Throughout the study, various tests and observations will be conducted to assess the medication’s impact. These include checking bladder function, monitoring for any leakage episodes, and evaluating the overall acceptability of the treatment. The study will also involve regular health checks, such as vital signs and laboratory tests, to ensure the safety of the participants. The results will help determine if Mirabegron is a suitable treatment option for young children with Neurogenic Detrusor Overactivity.

]]>